Venture&Growth
Location
Murray Hill (NJ), USA
Venture&Growth
All Portfolio items
See full Venture&Growth portfolio
FlowCardia is a medical device company marketing catheters that reopen obstructed arteries in the legs, which can avoid amputation. Its lead product, the CROSSER™, uses high-frequency vibration to penetrate hard arterial blockages.
After Gilde led a large institutional financing round of growth capital, the company built a marketing and sales organization, expanded its product portfolio and developed into a high-growth, revenue-generating business. FlowCardia was acquired by C. R. Bard, Inc. (NYSE: BCR) in 2010. It was located in Sunnyvale, California.
More Flowcardia news
FlowCardia, Inc. Initiates CENTRAL Study Enrollment
FlowCardia, Inc. expands treatment options for patients with chronic total occlusion
FlowCardia, Inc. Launches FlowMate™ Injector to Optimize Performance
FlowCardia, Inc. Appoints Deborah DeFilippo CFO
Venture&Growth
Calypso Biotech
Dutch Therapeutics company focused on severe (auto) immune diseases.
Venture&Growth
Karius, Inc.
Karius is a U.S.-based diagnostic company that develops and commercializes an AI-based liquid biopsy test to diagnose serious infections in immunocompromised patients and other hospitalized patients. The company is commercial in the U.S. and provides strong potential for better care
Venture&Growth
Wellinks / Spire Health
US-based Healthtech company providing remote patient monitoring solutions for COPD patients.
